AIMS/HYPOTHESIS: Diets rich in n-3 polyunsaturated fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against insulin resistance and obesity in rodents and increase insulin sensitivity in healthy humans. We tested whether the anti-diabetic effects of EPA and DHA involve enhanced production of the endogenous insulin sensitiser, adiponectin. METHODS: We studied the effects, in an obesity-promoting high-fat diet, of partial replacement of vegetable oils by EPA/DHA concentrate (6% EPA, 51% DHA) over a 5-week period in adult male C57BL/6J mice that either had free access to food or had their food intake restricted by 30%. At the end of the treatment, systemic markers of lipid and glucose metabolism and full-length adiponectin and leptin were measured. Adiponectin (Adipoq) and leptin (Lep) gene expression in dorsolumbar and epididymal white adipose tissue (WAT) and isolated adipocytes was quantified and adipokine production from WAT explants evaluated. RESULTS: In mice with free access to food, plasma triacylglycerols, NEFA, and insulin levels were lower in the presence of EPA/DHA, while glucose and leptin levels were not significantly altered. Food restriction decreased plasma triacylglycerols, glucose, insulin and leptin, but not adiponectin. EPA/DHA increased plasma adiponectin levels, independent of food intake, reflecting the stimulation of Adipoq expression in adipocytes and the release of adiponectin from WAT, particularly from epididymal fat. Expression of Lep and the release of leptin from WAT, while being extremely sensitive to caloric restriction, was unaltered by EPA/DHA. CONCLUSIONS/ INTERPRETATION: Intake of diets rich in EPA and DHA leads to elevated systemic concentrations of adiponectin, largely independent of food intake or adiposity and explain, to some extent, their anti-diabetic effects.
AIMS/HYPOTHESIS: Diets rich in n-3 polyunsaturated fatty acids, namely eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), protect against insulin resistance and obesity in rodents and increase insulin sensitivity in healthy humans. We tested whether the anti-diabetic effects of EPA and DHA involve enhanced production of the endogenous insulin sensitiser, adiponectin. METHODS: We studied the effects, in an obesity-promoting high-fat diet, of partial replacement of vegetable oils by EPA/DHA concentrate (6% EPA, 51% DHA) over a 5-week period in adult male C57BL/6J mice that either had free access to food or had their food intake restricted by 30%. At the end of the treatment, systemic markers of lipid and glucose metabolism and full-length adiponectin and leptin were measured. Adiponectin (Adipoq) and leptin (Lep) gene expression in dorsolumbar and epididymal white adipose tissue (WAT) and isolated adipocytes was quantified and adipokine production from WAT explants evaluated. RESULTS: In mice with free access to food, plasma triacylglycerols, NEFA, and insulin levels were lower in the presence of EPA/DHA, while glucose and leptin levels were not significantly altered. Food restriction decreased plasma triacylglycerols, glucose, insulin and leptin, but not adiponectin. EPA/DHA increased plasma adiponectin levels, independent of food intake, reflecting the stimulation of Adipoq expression in adipocytes and the release of adiponectin from WAT, particularly from epididymal fat. Expression of Lep and the release of leptin from WAT, while being extremely sensitive to caloric restriction, was unaltered by EPA/DHA. CONCLUSIONS/ INTERPRETATION: Intake of diets rich in EPA and DHA leads to elevated systemic concentrations of adiponectin, largely independent of food intake or adiposity and explain, to some extent, their anti-diabetic effects.
Authors: P Flachs; O Horakova; P Brauner; M Rossmeisl; P Pecina; N Franssen-van Hal; J Ruzickova; J Sponarova; Z Drahota; C Vlcek; J Keijer; J Houstek; J Kopecky Journal: Diabetologia Date: 2005-10-05 Impact factor: 10.122
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: Jana Ruzickova; Martin Rossmeisl; Tomas Prazak; Pavel Flachs; Jana Sponarova; Marek Veck; Eva Tvrzicka; Morten Bryhn; Jan Kopecky Journal: Lipids Date: 2004-12 Impact factor: 1.880
Authors: P Wellhoener; B Fruehwald-Schultes; W Kern; D Dantz; W Kerner; J Born; H L Fehm; A Peters Journal: J Clin Endocrinol Metab Date: 2000-03 Impact factor: 5.958
Authors: Gabriela Suchankova; Michael Tekle; Asish K Saha; Neil B Ruderman; Steven D Clarke; Thomas W Gettys Journal: Biochem Biophys Res Commun Date: 2005-01-28 Impact factor: 3.575
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: Adriano M de Assis; Anderson Rech; Aline Longoni; Liane N Rotta; Cristiane C Denardin; Matheus A Pasquali; Diogo O Souza; Marcos L S Perry; José C Moreira Journal: Mol Cell Biochem Date: 2011-10-12 Impact factor: 3.396
Authors: Tomas Jelenik; Martin Rossmeisl; Ondrej Kuda; Zuzana Macek Jilkova; Dasa Medrikova; Vladimir Kus; Michal Hensler; Petra Janovska; Ivan Miksik; Marcin Baranowski; Jan Gorski; Sophie Hébrard; Thomas E Jensen; Pavel Flachs; Simon Hawley; Benoit Viollet; Jan Kopecky Journal: Diabetes Date: 2010-08-06 Impact factor: 9.461
Authors: O Kuda; T Jelenik; Z Jilkova; P Flachs; M Rossmeisl; M Hensler; L Kazdova; N Ogston; M Baranowski; J Gorski; P Janovska; V Kus; J Polak; V Mohamed-Ali; R Burcelin; S Cinti; M Bryhn; J Kopecky Journal: Diabetologia Date: 2009-03-11 Impact factor: 10.122
Authors: Catalin Mindrescu; Rakesh P Gupta; Eileen V Hermance; Mary C DeVoe; Vikas R Soma; John T Coppola; Cezar S Staniloae Journal: Vasc Health Risk Manag Date: 2008